下一代抗体偶联药物的发展与挑战
抗体偶联药物(ADC)由单克隆抗体连接载荷构成,旨在向癌细胞递送高浓度细胞毒药物。对ADC作用与耐药机制的理解推动了化学结构进展和合理联合治疗,但创新速度已超临床试验能力,且单一修饰难以产生临床获益。需整合多重化学进展并建立框架加速临床前与早期临床开发,开发多维分子工具预测ADC敏感性,长期看多样化ADC库有望实现个体化治疗。
要点
- ADC创新速度超过临床试验能力,单一修饰或组合难以独立产生临床获益。
- 需整合多重化学进展到单个ADC,并建立框架加速临床前与早期临床开发。
- 开发多维分子工具预测ADC敏感性,长期多样化ADC库可支持个体化治疗。
核心结论
- ADC创新速度已超临床试验能力,单一修饰或组合难以独立产生临床获益。
- 需整合多重化学进展并建立框架加速临床前与早期临床开发以降低风险。
- 长期看多样化ADC库结合个体肿瘤生物学可实现个体化治疗策略。
研究设计与样本
- 本文为综述/观点文章,讨论ADC的机遇与挑战,未报告系统检索范围。
主要发现
- 对ADC作用机制和耐药机制的深入理解推动了ADC构建化学和合理联合治疗的进展。
- 任何单一修饰或组合不太可能单独产生有临床意义的获益。
- 开发多维分子工具预测ADC敏感性及在早期癌症中优化使用新ADC应有助于改善患者结局。
临床怎么用
- 需整合多重化学进展到单个ADC并建立框架、基础设施和工具以加速临床前与早期临床开发。
- 应开发多维分子工具预测ADC敏感性,并在早期癌症中优化使用新ADC。
局限性
- 本文为观点/综述,未报告原始研究数据、样本量或统计阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-drug conjugates (ADCs)-composed of a monoclonal antibody linked to a payload-were designed to deliver high concentrations of cytotoxic agents to cancer cells. Since their inception, a deeper understanding of the mechanisms of action and resistance to ADCs in patients has generated a wealth of advances in the chemistry of ADC constructs, together with rational therapeutic combinations. However, the pace of innovation now exceeds clinical trial capacity. Also, any single modification or combination is unlikely to generate clinically meaningful benefit on its own. In this context, there is a need to integrate multiple chemistry advances into individual ADCs and to develop frameworks, infrastructures and tools to accelerate and de-risk the preclinical and early clinical development of these agents. In addition, the development of multidimensional molecular tools to predict ADC sensitivity, together with the optimal use of new ADCs in early-stage cancers, should contribute to improved outcomes for patients. We discuss these opportunities and challenges and predict that in the longer term, the development of diversified ADC libraries incorporating distinct constructs and drug-to-antibody ratios will enable personalized treatment strategies aligned with individual tumor biology.
引用
- Mosele F, Peltier A, Ozaki Y, et al. The next generation of antibody-drug conjugates. Nat Med. 2026. PMID: 42547622. doi:10.1038/s41591-026-04543-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。